1. Upfront sentinel lymph node biopsy permitted the avoidance of axillary lymph node dissection in most patients with cN1 HR+/HER2- breast cancer and limited ultrasound findings. 2. Sentinel lymph ...
The 3-year axillary RFS rate was 99.2% with axillary lymph node dissection and 98.8% with less-invasive procedures. Less-invasive lymph node procedures are noninferior to axillary lymph node ...
Limited data are available on survival outcomes after sentinel-lymph-node biopsy alone as compared with lymphadenectomy in cervical cancer. In this multicenter, randomized, noninferiority trial, we ...
Response-guided axillary treatment using an approach known as the MARI protocol can safely spare many women with node-positive breast cancer from axillary lymph node dissection (ALND) after ...
A pilot program in six states will use a tactic employed by private insurers that has been heavily criticized for delaying and denying medical care. By Reed Abelson and Teddy Rosenbluth Like millions ...
Following propensity score matching, the comparative results between the two groups remained statistically non-significant. The five-year axillary recurrence-free survival (ARFS) rate was 99.2% for ...
Dr. Ko Un “Clara” Park and Dr. Mylin Torres present the latest evidence-based changes to the SLNB in early-stage breast cancer guideline. They discuss the practice-changing trials that led to the ...
Targeted axillary dissection (TAD) emerged as the optimal minimally invasive technique, demonstrating superior diagnostic accuracy over other approaches in patients with node-positive breast cancer ...
High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial These results are similar to those in patients undergoing ...
TCT 1235: Multiple Percutaneous Transaxillary Large Bore Procedures Through the Same Axillary Artery
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...
Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited ...
The concept of skipping axillary lymph node dissection (ALND) in some patients with breast cancer was supported by a European noninferiority trial. Among patients with early-stage, node-negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results